Related Experiment Video
Updated: Feb 13, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
A purpurin-based metalloimmunostimulant amplifies ROS and modulates STING/TNF-α axis to potentiate melanoma
Xiaoxin Yang1, Mi Huang1, Tianyi Pang1
1Central South University (Department of Dermatology, Xiangya Hospital, Department of Radiology, Second Xiangya Hospital of Central South University, Furong Laboratory), Changsha, Hunan, 410008, China.
None:
The low infiltration of pro-inflammatory immune cells and the sustained activation of multiple immunosuppressive signaling pathways in melanoma significantly limit the efficacy of clinical immunotherapy. Therefore, developing an effective immunostimulant with reversing the immunosuppressive tumor microenvironment (TME) is of great significance for improving melanoma immunotherapy. Herein, a degradable metalloimmunostimulant (PurpN/Mn@PEG) is developed for immunotherapy targeting immunosuppressive melanoma. The PurpN/Mn@PEG NPs are fabricated by coordination-driven self-assembly of purpurin and Mn2+, followed by polyethylene glycol (PEG) modification. PurpN/Mn@PEG dissociates in acidic pH and high glutathione TME, releasing PurpN and Mn2+. The nanoparticle exhibits peroxidase-/oxidase-like activity, generating a reactive oxygen species (ROS) storm that induces immunogenic cell death. PurpN/Mn@PEG amplifies ROS via H2O2 production through phenolic oxidation, enhances TNF-α secretion via CCAAT/enhancer-binding protein beta (CEBPB) upregulation, and sensitizes cGAS-STING pathway, synergistically boosting melanoma immunotherapy. In vivo experiments demonstrated that this purpurin-based metalloimmunostimulant exhibits remarkable therapeutic efficacy with an 87.8 % tumor growth inhibition rate in B16-F10 melanoma-bearing mice by activating multiple immune pathways, thereby effectively augmenting melanoma immunotherapy. This study provides an innovative therapeutic strategy that effectively reprograms the immunosuppressive TME to potentiate melanoma immunotherapy.
More Related Videos
07:31Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs
Published on: May 24, 2016
16:07Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method
Published on: September 16, 2017
Related Concept Videos
Operational Amplifiers
MOSFET Amplifiers
BJT Amplifiers
In BJT amplifier configurations, particularly in common-emitter setups, the transistor's role...
Tumor Immunotherapy
Factors Affecting α-Alkylation of Ketones: Choice of Base
The reaction involving bases like EtO− whose conjugate acid EtOH (pKa = 15.9) is stronger than the ketone (pKa = 19.2) results in an equilibrium mixture with higher ketone concentration. As a consequence,...
Base-Promoted α-Halogenation of Aldehydes and Ketones